Drug Type Protein drugs |
Synonyms CSL-889 |
Target |
Action modulators |
Mechanism HPX modulators(hemopexin modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anemia, Sickle Cell | Phase 3 | United States | 10 Jul 2025 | |
| Anemia, Sickle Cell | Phase 3 | Belgium | 10 Jul 2025 | |
| Anemia, Sickle Cell | Phase 3 | Italy | 10 Jul 2025 | |
| Anemia, Sickle Cell | Phase 3 | Spain | 10 Jul 2025 | |
| Anemia, Sickle Cell | Phase 3 | Turkey | 10 Jul 2025 | |
| Vaso-occlusive crisis | Phase 3 | United States | 10 Jul 2025 | |
| Vaso-occlusive crisis | Phase 3 | Belgium | 10 Jul 2025 | |
| Vaso-occlusive crisis | Phase 3 | Italy | 10 Jul 2025 | |
| Vaso-occlusive crisis | Phase 3 | Spain | 10 Jul 2025 | |
| Vaso-occlusive crisis | Phase 3 | Turkey | 10 Jul 2025 |
Phase 1 | 28 | (Part A) | hxghhjcsuw(iytpgtjsje) = Seventy treatment emergent adverse events (TEAEs) were reported in 22 subjects (51 mild, 18 moderate and 1severe). Number or severity of TEAEs did not increase with dose or VOC status. The most common TEAEs were sickle cell anemia with crisis (29% of subjects, all ≥1 week after CSL889) and headache (17%). lxtucsmlms (okqqpxhtlm ) View more | Positive | 14 May 2024 | ||
(Part B) |






